̽»¨¾«Ñ¡

I received my PhD degree from the Karolinska Institute, where my research focused on investigating the utility of transcriptional gene expression signatures to enhance therapy selection accuracy and improve outcomes for cancer patients.

During my initial postdoctoral appointment at Stanford University in 2019, I conducted research in the field of personalized cancer medicine. Specifically, I explored "immune hot" cancer types such as Triple Negative Breast Cancer, Colorectal Cancer, and Melanoma, with the goal of advancing our understanding of these diseases and improving treatment strategies.

Subsequently, in 2020, I joined the University of California, San Francisco, where I became an integral part of a laboratory that made significant contributions to the StandUp2 Cancer WCDT cohort. This cohort represents the largest gathering of patients with metastatic castration-resistant prostate cancer (mCRPC) in the United States. I then joined the Institute of Cancer Research and Royal Marsden Hospital in London, UK, where I hold a senior postdoctoral scholar position within Prof. Johann de Bono's lab studied translation aspects of prostate cancer disease. 
In 2024, I awareded with ScilifeLab-Knut and Alice Wallenberg's Data-Driven Life Science (DDLS) fellowship in Precision medicine and Diagnostics to establish my own lab at the KTH Royal Institute of Technology where my lab focuses on the impact of inflammation and microbiome on cancer progression. Please find further details here: www.alundberg.org

My primary research interest revolves around investigating the intricate interplay between genomic and epigenomic changes in cancer development and progression, with a specific focus on prostate cancer. To comprehensively explore this field, I utilize cutting-edge multi-omics approaches, such as Whole Genome Sequencing, RNA-seq, and Whole Genome Bisulfite Sequencing. Additionally, I incorporate ATAC-sequencing to gain valuable insights into the chromatin accessibility landscape. By conducting integrative research work in patients with prostate cancer, I aim to identify
key molecular alterations that contribute to disease pathogenesis and ultimately pave the way for improved diagnostic and therapeutic strategies.